Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00423007 | Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis | PHASE3 | COMPLETED | 90 | — | — | Nov 1, 2006 | Aug 1, 2007 | Mar 14, 2013 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Bromfenac | EXPERIMENTAL | Ophthalmic Solution |
| Placebo | PLACEBO_COMPARATOR | Vehicle ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| Bromfenac | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * History of clinically active allergic conjunctivitis * Agree to return for all required visits * Agree to avoid disallowed meds Exclusion Criteria: * Known hypersensitivity to bromfenac and salicylates